# Polycythemia Vera" FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/polycythemia-vera

> 6 upcoming FDA catalysts in polycythemia Vera": MIMRYLO™ (rusfertide, TAK) on Oct 2027 to Jan 2028 (topline data readout); MIMRYLO™ (rusfertide, TAK) on October 2027 (primary completion); MIMRYLO™ (rusfertide, TAK) on July 2028 (primary completion); MIMRYLO™ (rusfertide, TAK) on Jul to Oct 2028 (topline data readout); and 2 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| March 3, 2025 | [MIMRYLO™ (rusfertide) topline data readout](https://sec-api.dev/pdufa/rusfertide) | TAK | Polycythemia Vera" | completed, positive | "The topline results of this study were announced on March 3, 2025, in "Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera"." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1395064/000139506425000164/form6k_120825.htm)) |
| April 2026 | [Open-label rusfertide primary completion](https://sec-api.dev/pdufa/open-label-rusfertide) | PTGX | Polycythemia Vera | delayed | "NCT06033586 (Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-04-01 (ESTIMATED); Lead Sponsor Protagonist Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06033586)) |
| Oct 2027 to Jan 2028 | [MIMRYLO™ (rusfertide) topline data readout](https://sec-api.dev/pdufa/rusfertide) | TAK | Polycythemia Vera | scheduled | "NCT07648030 (A Study of Rusfertide in Japanese Adults With Polycythemia Vera): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10-28 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07648030)) |
| October 2027 | [MIMRYLO™ (rusfertide) primary completion](https://sec-api.dev/pdufa/rusfertide) | TAK | Polycythemia Vera | scheduled | "NCT07648030 (A Study of Rusfertide in Japanese Adults With Polycythemia Vera): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10-28 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07648030)) |
| July 2028 | [MIMRYLO™ (rusfertide) primary completion](https://sec-api.dev/pdufa/rusfertide) | TAK | Polycythemia Vera | scheduled | "NCT07765602 (A Study of Rusfertide in Adults With Polycythemia Vera in China): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-07-01 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07765602)) |
| Jul to Oct 2028 | [MIMRYLO™ (rusfertide) topline data readout](https://sec-api.dev/pdufa/rusfertide) | TAK | Polycythemia Vera | scheduled | "NCT07765602 (A Study of Rusfertide in Adults With Polycythemia Vera in China): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2028-07-01 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07765602)) |
| August 2030 | [AG-236 primary completion](https://sec-api.dev/pdufa/ag-236) | AGIO | Polycythemia Vera | scheduled | "NCT07859423 (A Study to Investigate AG-236 in Subjects ≥18 Years of Age With Polycythemia Vera): Overall Status NOT_YET_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-08 (ESTIMATED); Lead Sponsor Agios Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07859423)) |
| Aug to Nov 2030 | [AG-236 topline data readout](https://sec-api.dev/pdufa/ag-236) | AGIO | Polycythemia Vera | scheduled | "NCT07859423 (A Study to Investigate AG-236 in Subjects ≥18 Years of Age With Polycythemia Vera): Overall Status NOT_YET_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-08 (ESTIMATED); Lead Sponsor Agios Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07859423)) |

## Drugs

- [MIMRYLO™ (rusfertide)](https://sec-api.dev/pdufa/rusfertide) (TAK)
- [Open-label rusfertide](https://sec-api.dev/pdufa/open-label-rusfertide) (PTGX)
- [AG-236](https://sec-api.dev/pdufa/ag-236) (AGIO)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/polycythemia-vera.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Polycythemia Vera" FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/polycythemia-vera

```bibtex
@misc{secapidev_indications_polycythemia_vera_20261116,
  title        = {Polycythemia Vera" FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/polycythemia-vera}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_polycythemia_vera_20261116","title":"Polycythemia Vera\" FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/polycythemia-vera","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
